Myeloma cells and their interactions with the bone marrow endothelial cells

Current Immunology Reviews

Volumn 3, Issue 1, 2007, Pages 41-55

  De Bruyne, Elke ^a   Menu, Eline ^a   Van Valckenborgh, Els ^a   De Raeve, Hendrik ^b   Van Camp, Ben ^a   Van Riet, Ivan ^a   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Bone marrow microenvironment; Bone marrow stromal cells; Endothelial cells; Multiple myeloma

Indexed keywords

2 METHOXYESTRADIOL; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AE 941; ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; ATIPRIMOD; BEVACIZUMAB; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE INHIBITOR; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; SEMAXANIB; SORAFENIB; SUNITINIB; TELOMERASE INHIBITOR; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VATALANIB; VINCRISTINE; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; LYMPHOCYTE HOMING; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PARACRINE SIGNALING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; STROMA CELL; TERATOGENICITY; TUMOR IMMUNITY; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 34247216765     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339507779802151     Document Type: Review

References (232)

1. Bataillé R, Harousseau JL. Multiple Myeloma. N Eng J Med 1997; 336, 1657-4.
2. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77:2688-93.
3. Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84:2269-77.
4. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-87.
5. Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Myeloma cells (5TMM) and their interactions with the marrow environment. Blood Cells Mol Dis 2004; 33: 111-9.
6. Bakkus MHC, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326-35.
7. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-6.
8. Kyle RA, Rajkumar SV. Multiple Myeloma. N Eng J Med 2004; 351: 1860-73. Erratum in: N Engl J Med 2005; 352:1163
9. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (Re1B/p50) in myeloma. Oncogene 2003; 22: 2417-21.
10. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2005; 132: 385-97.
11. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927-37.
12. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004; 6:439-44.
13. Podar K, Anderson KC. The pathophysiological role of VEGF in hematological malignancies: therapeutic implications. Blood 2005; 105: 1383-95.
14. Mitsiades CS, Mitsiades N, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42: 1564-73.
15. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-8.
16. De Raeve H, Van Marck E, Van Camp B, Vanderkerken K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Hisopathol 2004; 19: 935-50.
17. Watson ML. Chemokines- Linking receptors to response. Immunology 2002; 105: 121-4.
18. Tanaka T, Bai Z, Srinoulprasert Y, Yang B, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005; 96: 317-22. Erratum in: Cancer Sci 2005; 96: 534.
19. Vanderkerken K, Vande Broeck I, Eizerik DL, et al. Monocyte Chemoattractant Protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5TMM cells. Clin Exp Metastasis 2002; 19: 87-90.
20. Radl J, De Glopper E, Schuit HRE. Idiopathic paraproteinemia II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979; 122: 609-13.
21. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 2003; 194:196-206.
22. Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I, Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003; 88: 855-62.
23. Pellegrino A, Ria R, Di Pietro G, et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasm cells. Br J Haematol 2005; 129: 248-56.
24. Arendt BK, Velazquez-Dones A, Tschumper RC, et al. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 2002; 16: 2142-7.
25. Johrer K, Janke K, Krugmann J, Fiegl M, Greil R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 2004; 10: 1901-10.
26. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003; 170: 1136-40.
27. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003; 17: 203-10.
28. Hideshima, T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-la in multiple myeloma. Mol Cancer Ther 2002; 1: 539-44.
29. Menu E, Asosingh K, Indraccolo S, et al. The involvement of stromal derived factor lα in homing and progression of multiple myeloma in the 5TMM model. Haematologica. 2006; 91: 605-12.
30. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor for human multiple myeloma cell lines. Blood 1996; 88: 2250-8.
31. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor I induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626-34.
32. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999; 93: 235-41.
33. Asosingh K, Gunthert U, Bakkus MH, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res 2000; 60: 3096-104.
34. Qiang YW, Yao L, Tosato G, Rudikoff S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 2004; 103: 301-8.
35. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 2003; 63: 5850-58. Erratum in: Cancer Res 2003; 63: 7543.
36. Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006, in press.
37. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein-1 alpha (MIP-1 alpha) triggers migration and signallirig cascades mediating survival and proliferation in multiple myeloma (MM cells. Blood 2003; 101: 3568-73.
38. Vande Broek I, Vanderkerken K, De Greef C, et al. Laminin-1 induced migration of Multiple Myeloma cells involves the high affinity 67kD Laminin Receptor. Br J Cancer 2001; 85: 1387-95.
39. Van Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76:377-82.
40. Van Riet I, Do Waele M, Remels L, Lacor P, Schots R, Van Camp B. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol 199l; 79:42l-7.
41. Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol 1992; 81: 331-5.
42. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992; 80:2306-14.
43. Pellat-Deceunynck C, Barille S, Puthier D, et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumour spreading, and immortalization. Cancer Res 1995; 55: 3647-53.
44. Faid L, Van Riet I, De Waele M, et al. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Eur J Haematol 1996; 57: 349-58.
45. Van Driel M, Gunthert U, van Kessel AC, et al. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia 2002; 16:135-43.
46. Stauder R, Van Driel M, Schwarzler C, et al. Differentt CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood 1996; 88:3101-8.
47. U. Gunthert. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993; 184: 47-63.
48. Asosingh K, Gunthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. A unique pathway in the homing of murine multiple myeloma, cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 2001; 61: 2862-5.
49. Okado T, Hawley RG. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int J Cancer 1995; 63: 923-30.
50. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13: 35-48.
51. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plamn cell adhesion to type I collagen. Blood 1993; 81: 767-74.
52. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002; 87: 836-45.
53. Kawano, MM, Huang N, Tanaka H, et al. Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules. Br J Haematol 1991; 79: 583-8.
54. Damiano S, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-67.
55. Damiano S, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000; 38:71-81.
56. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-8.
57. Kelly T, Borset M, Abe E, Gaddy-Kurten D, Sanderson RD. Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma 2000; 37:273-81.
58. Noel A, Gilles C, Bajou K, et al. Emerging roles for proteinases in cancer. Invasion Metastasis 1997; 17: 221-39.
59. Barrile S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997; 90:1649-55.
60. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995; 154:4379-89.
61. Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloprotainase-2 activation. J Immunol 1999; 163: 5723-8.
62. Van Valckenborgh E, Bakkus M, Munaut C, et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 2002; 101: 512-8.
63. Vande Broek I, Asosingh K, Allegaert V, et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004; 18: 976-9.
64. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16:2610-20.
65. Asosingh K, Menu E, Van Valckenborgh E. et al. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin Exp Metastasis 2002; 19: 583-91.
66. Giuliani N, Colla S, Rizolli V. Angiogenic switch in multiple myeloma. Haematology 2004; 9: 377-81.
67. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
68. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
69. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
70. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003; 9: 1144-55.
71. Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K. Matrix metalloproteinases in multiple myeloma. Cancer Ther 2004; 2: 29-38.
72. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
73. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111-6.
74. Sezer O, Niemöller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients of multiple myeloma. Ann Hematol 2000; 79: 574-7.
75. Pruneri G, Ponzoni M, Ferreri AJ, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002; 118: 817-20.
76. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-74.
77. Van Valckenborgh E, De Raeve H, Devy L, et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 2002; 86: 796-802.
78. Asosingh K, De Raeve H, Menu E, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 2004; 103: 3131-7.
79. De Raeve H, Asosingh K, Wisse E, Van Camp B, Van Marck E, Vanderkerken K. Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model. Virchows Arch. 2004; 445: 389-95.
80. Ribatti D, Scavelli C, Roccaro AM, Crivellato E, Nico B, Vacca A. Hematopoietic cancer and angiogenesis. Stem Cells Dev 2004; 13: 484-95.
81. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184-91.
82. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular growth factor and its receptors in hematological malignancies. Blood 1999; 59: 728-33.
83. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal interactions in multiple myeloma. Blood 2000; 95: 2630-6.
84. Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the P13K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 2004; 90:1076-83.
85. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
86. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88: 176-85.
87. Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor ant interleukin-6 in multiple myeloma. Blood 2003; 101: 2775-83.
88. Gupta D, Treon SP, Shima, Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950-61.
89. Colla S, Morandi F, Lazzaretti M, et al. Do human myeloma cells directly produce basic FGF? Blood 2003; 102: 3071-2.
90. Giuliani N, Colla S, Lazzaretti M, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102:638-45.
91. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405-7.
92. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signalling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-35.
93. Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-31.
94. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of the myeloma cells is associated with beta 1 integrin-and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002; 277: 7875-81.
95. Bergui L., Schena M, Gaidano G, Riva M, Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 1989; 170: 613-8.
96. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-26.
97. Chauhan D, Kharbanda S, Ogato A. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997; 89: 227-34.
98. Taga T. The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Ann Med 1997; 29: 63-72.
99. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991-6000.
100. Kudo O, Sabokhar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-inpedendent mechanism. Bone 2003; 32: 1-7.
101. Vincent T and Mechti N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004; 18: 967-75.
102. Zhang XG, Gu JJ, Lu ZY, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994; 179: 1337-42.
103. Gaillard JP, Liautard J, Klein B, Brochier J. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines. Eur J Immunol 1997; 27: 3332-40.
104. Thabard W, Barille S, Collette M, et al. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage. Clin Cancer Res 1999; 5: 2693-7.
105. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-5.
106. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991; 77: 587-93.
107. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712-20.
108. Thomas Y, Anglaret B, Magaud JP, Epstein J, Archimbaud E. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk Lymphoma 1998; 32: 107-19.
109. Carter A, Merchav S, Silvain-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990; 74: 424-31.
110. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in human multiple myeloma. Blood 1995; 85: 1903-12.
111. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483-9.
112. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008-11.
113. Thaler J, Fechner F, Herold M, Huber H. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leuk Lymphoma 1994; 12: 265-71.
114. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol 2005; 18: 509-24.
115. Suzuki H, Yasukawa K, Saito T, et al. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth vivo. Eur J Immunol 1992; 22: 1989-93.
116. Tassone P, Neri P, Burger R, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 2005; 11: 4251-8.
117. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-65.
118. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915-24.
119. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856-61.
120. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763-70.
121. Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997; 159: 487-96.
122. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997; 97: 429-40.
123. Nilsson K, Georgii-Hemming P, Spets H, Jemberg-Wiklund H. The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro. Curr Top Microbiol Immunol 1999; 246: 325-32.
124. Ogawa M, Nishiura T, Oritani K, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000; 60: 4262-9.
125. Abboud S, Bethel CR, Aron DC. Secretion of insulinlike growth factor I and insulin like growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest 1991; 88: 470-5.
126. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 873-7.
127. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 4138-46.
128. Mitsiades CS, Misiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma Cells: therapeutic implications. Oncogene 2002; 21: 5673-83.
129. Abroun S, Ishikawa H, Tsuyama N, et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. Blood 2004; 103: 2291-8. Erratum in: Blood 2004; 103: 2891.
130. Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002; 100: 3925-9.
131. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005; 90: 706-7.
132. Strömberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006; 107: 669-78.
133. Menu E, Jemberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006; 107: 655-60.
134. Podar K, Shringarpure R, Tai YT, et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004; 64: 7500-6.
135. Nakagawa M, Kaneda T, Arakawa T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161-4.
136. Henriksen K, Karsdal M, Delaissé JM, Engsig MT. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 2003; 278: 48745-53.
137. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the finctional maturation of dendritic cells. Nat Med 1996; 2: 1096-103. Erratum in: Nat Med 1996; 2: 1267.
138. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353-5.
139. Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069-73.
140. Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004; 103: 3521-8.
141. Trudel S, Li ZH, Wei E, et al. CHR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941-8.
142. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple mycloma patients. Cancer Res 2005; 65: 1700-9.
143. Van de Brook I, Leleu X, Schots R, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006; 91: 200-6.
144. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65: 465-72.
145. Sati HI, Greaves M, Apperly JF, Russell RG, Croucher PI. Expression of interleukin-Ibeta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 1999; 104: 350-7.
146. Hideshima, T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519-27.
147. Watanabe M, Dewan MZ, Okamura T, et al. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005; 114: 32-8.
148. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-47.
149. Molostvov G, Morris A, Rose P, Basu S, Muller G. The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. Br J Haematol 2004; 124: 366-75.
150. Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003; 102: 3340-8.
151. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-9.
152. Ria R, Vacca A, Russo F, et al. A VEGF-dependcat autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004; 92: 1438-45. Erratum in: Thromb Haemost 2005; 93: 397.
153. Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-9.
154. Sezer O, Heider U, Zavriski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-8.
155. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-9.
156. Seidel CO, Hjertner O Abildgaard D, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-71.
157. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates asteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003; 63: 5438-45.
158. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98: 11581-6.
159. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98: 3527-33.
160. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-91.
161. Okada T, Akikusa S, Okuno H, Kodaka M. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metatasis 2003; 20: 639-46.
162. Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microonvironment. Haematologica 2004; 89: 1118-23.
163. Mancuso P, Rabascio C, Bertolini F. Strategies to investigate circulating endothelial cells in cancer. Pathophysiol Haemost Thromb 2003/2004; 33: 503-6.
164. Hunting CB, Noort WA, Zwaginga JJ. Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization. Vox Sang 2005; 88: 1-9.
165. Beerepoot LV, Mehra N, Vermaat JSP, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15: 139-45.
166. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004; 8: 294-300.
167. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001; 61: 4341-4.
168. Mancuso P, Calleri A, Cassi C, et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003; 522: 83-97.
169. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79-88.
170. Blann AD, Pretorius A. Circulating endothelial cells and endothelial progenitor cells: Two sides of the same coin, or two different coins? Atherosclerosis 2006; 188: 12-8.
171. Asahara T, Murohara T, Sullivan A, et al Isolation of putative progenitor andothelial cells for angiogenesis. Science 1997; 275: 964-7.
172. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-35.
173. Ceradini DJ and Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005; 15: 57-63.
174. Hammerling GJ, Ganss R. Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle 2006; 5: 509-11.
175. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003; 9: 789-95.
176. Göthert JR, Gustin SE, van Eckelen JA, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute tumor and tumor endothelium. Blood 2004; 104: 1769-77.
177. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-9.
178. Dominici M, Campioni D, Lanza F, et al. Angiogenesis in multiple
179. Zhang H, Vakil L. Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286-94.
180. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006; 107: 2531-5.
181. Morgan GJ, Davies FE. Evolving treatinent strategies for myeloma. Br J Cancer 2005; 92: 217-21.
182. Kumar S. Progress in the treatinent of multiple myeloma. Lancet 2006; 367: 791-2.
183. Dalton WS. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Update 1999; 2: 285-288.
184. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005; 23: 6345-50.
185. Hussein MA. Multiple myeloma: an update of developments in targeted therapy. Expert Rev Anticancer Ther 2005; 5: 379-89.
186. Singnal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71. Erratum in: N Engl J Med 2000; 342: 364.
187. Barlogie B, Desikan E, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-4.
188. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002; 3: 185-92.
189. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69-77.
190. Rajkumar SV, Dispenzieri A. Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274-6.
191. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-23.
192. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-31.
193. Hussein MA. Thalidomide: present and future in multiple myeloma. Expert Rev Anticancer Ther 2005; 5: 25-31.
194. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5.
195. Yaccoby S, Johnson CL Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002; 100: 4162-8.
196. Kumar S, Witzig TE, Dispenzieri A. et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myleoma. Leukemia 2004; 18: 624-7.
197. Lentzsch S, Rogers MS, LeBlanc R, et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002; 62: 2300-5.
198. De Raeve H, Vanderkerken K. Immunomodulatory drugs as a therapy for multiple myeloma. Curr Pharma Biotechol 2006; 7: in press.
199. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-50.
200. Corral LG, Haslett PA, Muller GW, et al. Diffierential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-6.
201. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immuno-modulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-6.
202. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myleoma. Blood 2002; 100: 3063-7.
203. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269-76.
204. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptatic signaling induced by immunodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-30.
205. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 739-58.
206. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000; 18: 109-21.
207. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 2005; 45:465-76.
208. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
209. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003; 22: 8386-93.
210. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-9.
211. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
212. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-80.
213. Chng WJ, Lau LG, Yusof N, Mow BM. Targeted therapy in multiple myeloma. Cancer Control 2005; 12: 91-104.
214. Oikawa, T, Sasaki T, Nakamura K, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243-8.
215. Leblanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996-5000.
216. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-24.
217. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-70.
218. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-71.
219. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-60.
220. Hussein M, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004; 125: 470-6.
221. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-30.
222. Wang Y, Hu Y, Sun C, Zhang Y, He W. Mechanism of arsenic trioxide inhibiting angiogenesis in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 3-6.
223. Wood JM, Bold G, Buchdunger E, et al. PTK7/87/ZK 222594, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration. Cancer Res 2000; 60, 2178-2189.
224. Thomas AL, Morgan B, Drevs J, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222594. Semin Oncol 2003; 30: 32-8.
225. Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment Cancer Res 2002; 62: 5019-26.
226. Podar K, Catley LP, Tia YT, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004; 103: 3474-9.
227. Gingras D, Batist G, Beliveau R. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 2001; 1: 341-7.
228. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001; 28: 620-5.
229. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57: 81-6.
230. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237-9.
231. Chauhan D, Catley L, Hideshima T, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002; 100: 2187-94.
232. Dingli D, Timm M, Russell SJ, Witzig TE, Rajkumar SV. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res; 8: 3948-54.